Quantification of [3H]docetaxel in feces and urine: Development and validation of a combustion method

Anti-Cancer Drugs

Volumn 17, Issue 1, 2006, Pages 63-67

  Engels, Frederike K ^a   Buijs, Dirk ^a   Loos, Walter J ^a   Verweij, Jaap ^a   Bakker, Willem H ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Combustion method; Docetaxel; Liquid scintillation counting; Tritium; Validation

Indexed keywords

DOCETAXEL; ANTINEOPLASTIC AGENT; TAXOID; TRITIUM;

ANALYTIC METHOD; ARTICLE; CASE REPORT; COMBUSTION; DRUG EXCRETION; FECES ANALYSIS; HUMAN; LIQUID SCINTILLATION COUNTING; PRIORITY JOURNAL; RADIOACTIVITY; URINALYSIS; VALIDATION PROCESS; CHEMISTRY; FECES; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; NEOPLASM; REPRODUCIBILITY; SCINTILLATION COUNTING; URINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; FECES; HUMANS; INFUSIONS, INTRAVENOUS; NEOPLASMS; REPRODUCIBILITY OF RESULTS; SCINTILLATION COUNTING; TAXOIDS; TRITIUM;

EID: 33646094189     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000185183.57357.c2     Document Type: Article

References (17)

1. Bardelmeijer HA, Oomen IA, Hillebrand MJ, Beijnen JH, Schellens JH, van Tellingen O. Metabolism of paclitaxel in mice. Anticancer Drugs 2003; 14:203-209.
2. Bardelmeijer HA, Roelofs AB, Hillebrand MJ, Beijnen JH, Schellens JH, Tellingen OV. Metabolism of docetaxel in mice. Cancer Chemother Pharmacol 2005; 56:299-306.
3. Thorsgaard Pedersen N, Halgreen H. Simultaneous assessment of fat maldigestion and fat malabsorption by a double-isotope method using fecal radioactivity. Gastroenterology 1985; 88:47-54.
4. 35S in triply labeled organic samples by liquid scintillation counting. Anal Biochem 1990; 190:276-280.
5. 3H]formoterol in healthy men after combined i.v. and oral administration-mimicking inhalation. Drug Metab Dispos 1999; 27:1104-1116.
6. van den Bongard HJ, Kemper EM, van Tellingen O, Rosing H, Mathot RA, Schellens JH, et al. Development and validation of a method to determine the unbound paclitaxel fraction in human plasma. Anal Biochem 2004; 324:11-15.
7. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996; 56:1296-1302.
8. Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T. Metabolism of docetaxel by human cytochromes P450:interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996; 56:58-65.
9. Bruno R, Sanderink GJ. Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surv 1993; 17:305-313.
10. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 1995; 6:339-355.
11. 14C-RP 56976) in mice and dogs. Proc Am Ass Cancer Res 1993; 34:2343a.
12. Gaillard C, Monsarrat B, Vuilhorgne M, Royer I, Monegier B, Sable S, et al. Docetaxel (Taxotere) metabolism in the rat in vivo and in vitro. Proc Am Ass Cancer Res 1994; 35:2553a.
13. 14 radiolabeled Taxotere (TXT) (RP56976, NSC628503) in cancer patients. Proc Am Ass Cancer Res 1993; 34:2221a.
14. Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004; 75:448-454.
15. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004; 22:2489-2503.
16. US Food and Drug Administration. Guidance for industry bioanalytical method validation. Rockville: Center for Drug Evaluation and Research, Department of Health and Human Services; 2001.
17. Loos WJ, Verweij J, Nooter K, Stoter G, Sparreboom A. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 693:437-441.